← ACHV
What podcasts say about ACHV
Every statement, with the speaker, the exact quote and the moment it was said.
What experts have said about ACHV
3 statements · 1 positive · 2 negative
ACHV’s current product will probably pass its clinical trial.
“we actually think it's probably going to pass its clinical trial”
Open the episode · The Real Edge in Short-Selling Explained by Hedge Fund Ex-Analyst (ShortFinder CEO)Listen at 44:04
ACHV’s FDA approval catalyst will likely produce a rapid price pop and drop.
“there's going to be some kind of a lot of volatility where the stock price pops and then drops pretty quickly.”
Open the episode · The Real Edge in Short-Selling Explained by Hedge Fund Ex-Analyst (ShortFinder CEO)Listen at 45:32
ACHV’s 60% float increase will affect the stock.
“the effects one way or another of this 60% increase in the float are going to be felt.”
Open the episode · The Real Edge in Short-Selling Explained by Hedge Fund Ex-Analyst (ShortFinder CEO)Listen at 47:32
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.